The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. Issue 6 (3rd June 2019)
- Record Type:
- Journal Article
- Title:
- The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. Issue 6 (3rd June 2019)
- Main Title:
- The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications
- Authors:
- Vainchenker, William
Plo, Isabelle
Marty, Caroline
Varghese, Leila N.
Constantinescu, Stefan N. - Abstract:
- ABSTRACT: Introduction : Classical Myeloproliferative Neoplasms (MPNs) include three disorders: Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). MPNs are associated with constitutive activation of JAK2 leading to persistent cell signaling downstream of the dimeric myeloid cytokine receptors due to mutations in three genes encoding JAK2, calreticulin (CALR) and the thrombopoietin (TPO) receptor (MPL or TPOR). CALR and MPL mutants induce JAK2 activation that depends on MPL expression, thus explaining why they induce megakaryocyte pathologies including ET and PMF, but not PV. In contrast, JAK2 V617F drives all three diseases as it induces persistent signaling via EPOR, G-CSFR (CSF3R) and MPL. Areas Covered : Here, we review how different pathogenic mutations of MPL are translated into active receptors by inducing stable dimerization. We focus on the unique role of MPL on the hematopoietic stem cell (HSC), explaining why MPL is indispensable for the development of all MPNs. Last but not least, we describe how CALR mutants are pathogenic via binding and activation of MPL. Expert Opinion : Altogether, we believe that MPL is an important, but challenging, therapeutic target in MPNs that requires novel strategies to interrupt the specific conformational changes induced by each mutation or pathologic interaction without compromising the key functions of wild type MPL.
- Is Part Of:
- Expert review of hematology. Volume 12:Issue 6(2019)
- Journal:
- Expert review of hematology
- Issue:
- Volume 12:Issue 6(2019)
- Issue Display:
- Volume 12, Issue 6 (2019)
- Year:
- 2019
- Volume:
- 12
- Issue:
- 6
- Issue Sort Value:
- 2019-0012-0006-0000
- Page Start:
- 437
- Page End:
- 448
- Publication Date:
- 2019-06-03
- Subjects:
- Myeloproliferative neoplasms -- MPL/thrombopoietin receptor -- JAK2 -- calreticulin -- therapy
Hematology -- Periodicals
616.15005 - Journal URLs:
- http://www.expert-reviews.com/loi/ehm ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/17474086.2019.1617129 ↗
- Languages:
- English
- ISSNs:
- 1747-4086
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9830.227000
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 10685.xml